and another thing....from GHI's conference call....from Kim P:
"We also are pleased that the recently announced positive top line results from the QUASAR validation study evaluating our Oncotype DX colon cancer test have been accepted for oral presentation at the ASCO annual meeting.
Additionally, it is one of seven studies selected from more than 4,000 abstracts that will be featured in ASCOs Advanced Presscast on May 14th."
7 out of over 4000....ASCO must think it's pretty important too....
"The study did not meet its second endpoint evaluating a separate score, with a distinct set of genes, designed to predict which patients experience greater relative benefit of 5-fluorouracil/leucovorin (5FU/LV) following surgery."
This means insurance companies won't cover it, since it won't save them money. Chemotherapy is very expensive and if you can't reduce the number of patients undergoing it through classifying patient response (like the breast cancer test) the test won't save money. It will actually cost the insurance companies more money so they won't cover it.